Mink therapeutics announces closing of initial public offering

New york, oct. 19, 2021 (globe newswire) -- mink therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced the closing of its previously announced initial public offering of 3,333,334 shares of its common stock at a public offering price of $12.00 per share. all of the shares were offered by mink. the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $40.0 million. the shares began trading on the nasdaq global market on october 15, 2021 under the ticker symbol “inkt”.
INKT Ratings Summary
INKT Quant Ranking